



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office : Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2019

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Nine Month ended		Year ended
		31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	31-03-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	38,495.45	42,812.42	35,192.83	1,22,387.92	1,12,203.93	1,50,118.70
2	Other Income	1,602.19	1,810.70	1,557.92	4,646.64	2,493.65	4,022.50
3	Total Income (1+2)	40,097.64	44,623.12	36,750.75	1,27,034.56	1,14,697.58	1,54,141.20
4	Expenses						
	a. Cost of materials consumed	9,926.20	10,619.99	11,049.81	33,163.93	33,601.07	45,375.37
	b. Purchases of stock-in-trade	2,818.88	4,497.95	2,346.28	8,682.24	7,723.59	10,426.13
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	116.46	176.96	(1,964.69)	1,299.85	(2,263.92)	(2,165.74)
	d. Employee benefit expenses	7,355.40	6,969.05	6,475.90	21,388.56	19,039.62	25,797.86
	e. Finance Costs	85.28	87.43	126.93	253.08	325.73	411.51
	f. Depreciation and amortization expense	1,654.59	1,622.32	1,448.54	4,839.82	4,341.68	5,482.49
	g. Other Expenses	9,870.20	10,471.86	10,042.28	30,142.94	31,251.70	41,886.05
	Total Expenses (4)	31,827.01	34,445.56	29,525.05	99,770.42	94,019.47	1,27,213.67
5	Profit before Tax (3-4)	8,270.63	10,177.56	7,225.70	27,264.14	20,678.11	26,927.53
6	Tax expenses	2,053.37	581.63	2,588.35	5,536.31	6,689.70	8,721.61
7	Net Profit after Tax for the period (5-6)	6,217.26	9,595.93	4,637.35	21,727.83	13,988.41	18,205.92
8	Other Comprehensive Income (net of Tax)	(7.63)	(252.80)	(61.80)	(265.63)	(185.41)	29.25
9	Total Comprehensive Income after Tax (7+8)	6,209.63	9,343.13	4,575.55	21,462.20	13,803.00	18,235.17
10	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	7.75	11.96	5.64	27.08	17.02	22.15
	(2) Diluted	7.75	11.96	5.64	27.08	17.02	22.15

NOTES

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 4, 2020.
- The auditors have carried out limited review of the financial results for the quarter and nine months ended December 31, 2019 and their report does not contain any qualification.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Company has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the standalone financial results for the quarter and nine months ended December 31, 2019, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and nine months ended December 31, 2019 is not material. To this extent, performance for the quarter and nine months ended December 31, 2019 is not comparable with previous period results.
- The Company has completed the buy-back of 29,54,545 equity shares of Rs. 2 each @ Rs. 440 per share on January 8, 2020. Post this buy-back, the share capital of the Company stands reduced to Rs. 15,45,64,194 divided into 7,72,82,097 equity shares of Rs. 2 each.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

S.B.Mody
Whole time Director (Marketing)



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office : Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2019

Sl.No.	PART I - Particulars	Quarter ended			Nine Month ended		(Rs. in lakhs)
		31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	Year ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	42,863.25	45,641.70	38,202.62	1,33,115.98	1,22,428.49	1,64,320.04
2	Other Income	1,637.96	1,850.85	1,582.03	4,749.61	2,578.90	4,143.99
3	Total Income (1+2)	44,501.21	47,492.55	39,784.65	1,37,865.59	1,25,007.39	1,68,464.03
4	Expenses						
	a. Cost of materials consumed	9,970.78	10,582.95	11,049.81	33,171.47	33,601.07	45,375.37
	b. Purchases of stock-in-trade	5,403.09	6,190.59	3,490.22	14,690.65	12,380.45	16,209.91
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(339.09)	(102.98)	(1,901.18)	518.08	(2,732.68)	(1,939.38)
	d. Employee benefit expenses	8,231.58	7,702.17	7,225.87	23,739.16	21,347.37	28,817.59
	e. Finance Costs	85.32	87.39	129.70	253.08	334.02	419.81
	f. Depreciation and amortization expense	1,674.86	1,638.65	1,466.01	4,893.30	4,404.17	5,564.20
	g. Other Expenses	10,637.27	11,242.85	10,540.15	32,412.97	33,802.03	45,317.27
	Total Expenses (4)	35,663.81	37,341.62	32,000.58	1,09,678.71	1,03,136.43	1,39,764.77
5	Profit before Tax (3-4)	8,837.40	10,150.93	7,784.07	28,186.88	21,870.96	28,699.26
6	Tax expenses	2,192.72	774.62	2,788.94	5,954.76	7,153.02	9,302.29
7	Net Profit after Tax for the period (5-6)	6,644.68	9,376.31	4,995.13	22,232.12	14,717.94	19,396.97
8	Other Comprehensive Income (net of Tax)	696.45	(572.27)	(631.48)	315.82	(695.84)	(419.64)
9	Total Comprehensive Income after Tax (7+8)	7,341.13	8,804.04	4,363.65	22,547.94	14,022.10	18,977.33
10	Net Profit after Tax for the period attributable to:						
	- owners of the company	6,627.72	9,362.41	4,985.49	22,190.78	14,680.92	19,346.63
	- non controlling interest	16.96	13.90	9.64	41.34	37.02	50.34
11	Other comprehensive income for the period attributable to:						
	- owners of the company	671.00	(548.54)	(626.32)	305.01	(650.11)	(372.44)
	- non controlling interest	25.45	(23.73)	(5.16)	10.81	(45.73)	(47.20)
12	Total Comprehensive Income after Tax attributable to:						
	- owners of the company	7,298.72	8,813.87	4,359.17	22,495.79	14,030.81	18,974.19
	- non controlling interest	42.41	(9.83)	4.48	52.15	(8.71)	3.14
13	(i) Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	8.26	11.67	6.07	27.66	17.86	23.54
	(2) Diluted	8.26	11.67	6.07	27.66	17.86	23.54

- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 4, 2020.
- The auditors have carried out limited review of the consolidated financial results for the quarter and nine months ended on December 31, 2019 and their report does not contain any qualification.
- Indian Accounting Standard (Ind AS) - 116 "Leases" became effective from April 1, 2019 and the Group has adopted the same using modified retrospective transition method where at the date of initial application, the lease liability is measured at the present value of remaining lease payments and right of use asset has been recognised at an amount equal to the lease liability. In the consolidated financial results for the quarter and nine months ended December 31, 2019, Compensation Rent expenses has changed to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. The effect of adoption of Ind AS 116 on the results for the quarter and nine months ended December 31, 2019 is not material. To this extent, performance for the quarter and nine months ended December 31, 2019 is not comparable with previous period results.
- The consolidated financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements.
- The Holding Company has completed the buy-back of 29,54,545 equity shares of Rs. 2 each @ Rs. 440 per share on January 8, 2020. Post this buy-back, the share capital of the Holding Company stands reduced to Rs. 15,45,64,194 divided into 7,72,82,097 equity shares of Rs. 2 each.
- The Group has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

S.B.Mody
Whole time Director (Marketing)